Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma

Trial Profile

Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Interim results (n=67) assessing activity and tolerability of ixazomib plus thalidomide and dexamethasone, presented at the 22nd Congress of the European Haematology Association.
    • 06 Dec 2016 Interim analysis (n=39) was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top